Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• APG-3288 represents a strategic clinical stage candidate in the field of BTK-targeted therapies with high selectivity, potency, and consistent PK/PD profiles across multiple BTK-resistant models that validate differentiated design capabilities of PROTAC-based therapeutic candidates

  80% confidence

• APG-3288 is designed to act through degradation rather than inhibition, inducing rapid, potent, highly selective, and sustained degradation of both wild-type BTK and multiple BTK mutants associated with resistance to existing BTK inhibitors

  80% confidence

• In preclinical studies, APG-3288 demonstrated more potent BTK degradation, higher selectivity, and more favorable PK properties compared to other BTK degraders in development

  80% confidence

• Compared to existing conventional BTK inhibitors, Ascentage Pharma's BTK degraders developed with PROTAC technology can achieve complete degradation of target protein and are enabled by a molecular mechanism that can induce stronger efficacy

  80% confidence

• The FDA clearance marks a major milestone for the development of APG-3288 and strategic pipeline expansion that underscores persistent innovation in the field of hematologic malignancies and lays a strong foundation for future exploration of combinatory potential between APG-3288 and existing proprietary small-molecule agents

  80% confidence